AARTIDRUGS Aarti Drugs Q3 FY26 results (Oct–Dec 2025) and concall
Aarti Drugs reported an 8% YoY consolidated revenue growth to INR602.9 crores in Q3 FY26, with strong performance in its formulations segment. However, EBITDA declined 10% YoY to INR56.3 crores due to challenges like weak antibiotic demand, China shipment delays, a voluntary plant shutdown, and sub-optimal utilization of new facilities. The company is optimistic about an inflection point with stabilizing realizations and expects improved performance and margin expansion in coming quarters as new capacities ramp up and operational efficiencies improve.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 8.1%, net profit up 10.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 598 | 557 | 677 | 591 | 653 +9% | 602 +8% |
| EBITDA | 67 | 62 | 93 | 74 | 84 +25% | 55 −11% |
| Net profit | 35 | 37 | 63 | 54 | 45 +29% | 41 +11% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
